Time-to-event meta-analysis including 6 studies also revealed a similar, non-significant effect (HR: 0.85 [95% CI: 0.71 to 1.02], p = 0.06; I2 = 0%), Figure 8G. These findings suggest a possible stroke risk reduction in patients with diabetes treated with SGLT2 inhibitors, although this not reach statistical significance. The gene discussed is SLC5A2; the disease is stroke disorder.